Physician profile
Scott D Long
NPI 1477659506
$2,587.16
in general payments reported to CMS, 2019-2025
28 companies · $246 in 2025
The $246 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $580 · 2022: $612 · 2023: $661 · 2024: $488 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,395.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $959.60 | 2021-2025 | |
| Lilly USA, LLC | $244.88 | 2021-2023 | Mounjaro |
| Novo Nordisk INC | $191.69 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $155.83 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $107.87 | 2021-2023 | Verquvo, Belsomra |
| Pfizer INC. | $104.99 | 2021-2025 | |
| Amarin Pharma, INC. | $86.40 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.29 | 2022-2024 | Jardiance, Tradjenta, Synjardy |
| Teva Pharmaceuticals USA, INC. | $69.24 | 2022 | |
| Ironwood Pharmaceuticals, INC | $59.43 | 2021-2024 | Linzess |
| Idorsia Pharmaceuticals US INC | $53.75 | 2023-2024 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $49.19 | 2023 | Rexulti |
| Xeris Pharmaceuticals, INC. | $49.14 | 2022-2023 | Gvoke Hypopen |
| Kowa Pharmaceuticals America, INC. | $46.34 | 2022-2024 | Livalo, Seglentis |
| Takeda Pharmaceuticals U.S.A., INC. | $41.47 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $34.53 | 2022 | |
| Gilead Sciences, INC. | $32.78 | 2023 | |
| Shield Therapeutics INC | $29.32 | 2023-2024 | Accrufer |
| Mylan Specialty L.P. | $25.92 | 2024 | Yupelri |
| Dexcom, INC. | $21.43 | 2023 | Dexcom G6 Transmitter |
| Hologic Sales and Service, LLC | $19.98 | 2025 | Aptima |
| Biohaven Pharmaceutical Holding Company LTD. | $19.90 | 2022 | |
| Glaxosmithkline, LLC. | $19.70 | 2023 | Shingrix |
| Exact Sciences Corporation | $19.25 | 2025 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $18.95 | 2023 | |
| Paratek Pharmaceuticals, INC. | $16.27 | 2025 | Nuzyra |
| Cipher Pharmaceuticals US LLC | $14.84 | 2025 | Spinosad, Natroba |
| Genentech USA, INC. | $8.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.